Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer

Chi Kang Lin, Meng Yi Bai, Teh Min Hu, Yu Chi Wang, Tai Kuang Chao, Shao Ju Weng, Rui Lan Huang, Po Hsuan Su, Hung Cheng Lai

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.

Original languageEnglish
Pages (from-to)8993-9006
Number of pages14
JournalOncotarget
Volume7
Issue number8
DOIs
Publication statusPublished - 2016

Fingerprint

Niclosamide
Ovarian Neoplasms
Biological Availability
Neoplastic Stem Cells
Glycolysis
Growth
Antineoplastic Agents
Solubility
Oral Administration
Mitochondria
Parasites
Pharmacokinetics
Clinical Trials
Water
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cancer metabolism
  • Nanoformulation
  • Nanomedicine
  • Niclosamide
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. / Lin, Chi Kang; Bai, Meng Yi; Hu, Teh Min; Wang, Yu Chi; Chao, Tai Kuang; Weng, Shao Ju; Huang, Rui Lan; Su, Po Hsuan; Lai, Hung Cheng.

In: Oncotarget, Vol. 7, No. 8, 2016, p. 8993-9006.

Research output: Contribution to journalArticle

Lin, Chi Kang ; Bai, Meng Yi ; Hu, Teh Min ; Wang, Yu Chi ; Chao, Tai Kuang ; Weng, Shao Ju ; Huang, Rui Lan ; Su, Po Hsuan ; Lai, Hung Cheng. / Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. In: Oncotarget. 2016 ; Vol. 7, No. 8. pp. 8993-9006.
@article{1dbc1f9b48e34381bd2ead28f0110492,
title = "Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer",
abstract = "Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an {"}old{"} antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25{\%}). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.",
keywords = "Cancer metabolism, Nanoformulation, Nanomedicine, Niclosamide, Ovarian cancer",
author = "Lin, {Chi Kang} and Bai, {Meng Yi} and Hu, {Teh Min} and Wang, {Yu Chi} and Chao, {Tai Kuang} and Weng, {Shao Ju} and Huang, {Rui Lan} and Su, {Po Hsuan} and Lai, {Hung Cheng}",
year = "2016",
doi = "10.18632/oncotarget.7113",
language = "English",
volume = "7",
pages = "8993--9006",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "8",

}

TY - JOUR

T1 - Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer

AU - Lin, Chi Kang

AU - Bai, Meng Yi

AU - Hu, Teh Min

AU - Wang, Yu Chi

AU - Chao, Tai Kuang

AU - Weng, Shao Ju

AU - Huang, Rui Lan

AU - Su, Po Hsuan

AU - Lai, Hung Cheng

PY - 2016

Y1 - 2016

N2 - Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.

AB - Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.

KW - Cancer metabolism

KW - Nanoformulation

KW - Nanomedicine

KW - Niclosamide

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84961664624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961664624&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7113

DO - 10.18632/oncotarget.7113

M3 - Article

C2 - 26848771

AN - SCOPUS:84961664624

VL - 7

SP - 8993

EP - 9006

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -